Abstract：
Sphingolipids (SL) are well recognized for their cell signaling through extracellular and intracellular pathways. Based on chemistry different types of SL are biosynthesized in mammalian cells and have specific function in cellular activity. SL has an ampiphilic structure with have hydrophobic body attached to the polar head enables their use as a drug delivery agent in the form of nanocarriers. SL-based liposomes can improve the solubility of lipophilic drugs through host and drug complexes and are more stable than conventional liposomal formulations. Preclinical studies of SL nanocarriers are reported on topical delivery, oral delivery, ocular delivery, chemotherapeutic delivery, cardiovascular delivery and Alzheimer\'s disease. The commercial challenges and patents related to SL nanoformulations are highlighted in this article.
[Box: see text].
[Box: see text].
摘要：
鞘脂（SL）通过细胞外和细胞内途径的细胞信号传导被公认。基于化学,不同类型的SL在哺乳动物细胞中生物合成并且在细胞活性中具有特定功能。SL具有亲性结构,具有附着于极性头部的疏水体,使得它们能够以纳米载体的形式用作药物递送剂。基于SL的脂质体可以通过宿主和药物复合物改善亲脂性药物的溶解度，并且比常规脂质体制剂更稳定。据报道，SL纳米载体的临床前研究涉及局部递送，口服分娩，眼部分娩,化疗递送，心血管分娩和阿尔茨海默病。本文重点介绍了与SL纳米制剂相关的商业挑战和专利。
[方框：见正文]。
[方框：见正文]。
